G2-Peptide

G2-Peptide specifically binds to HS on the surface of Vero cells, which is confirmed by the reduced binding observed after heparinase III-mediated HS removal^[1].
G2-Peptide (2.5-20 mg/mL; 24 h) shows no cytotoxicity to Vero cells and HCE cells at concentrations of 2.5 mg/mL or lower, while cytotoxicity occurs at higher concentrations^[1].
The G2 peptide binds to discrete sites on the axonal surface of mature primary mouse hippocampal neurons^[3].
The G2 peptide specifically binds to sites on mouse synaptosomes, which is confirmed by dose-dependent competition assays with unlabeled G2 peptide^[3].
G2 peptide (0.1-10 μM) acutely and reversibly suppresses the electrical firing activity of mature primary mouse hippocampal neuron networks in a dose-dependent manner, achieving near-complete silencing at 10 μM^[3].
G2-Peptide (0.15-10 mg/well; 1 h) inhibits HSV-2 entry into HeLa cells, with the inhibitory effect reaching its peak at a concentration of 2.5 mg/well^[1].
G2-Peptide (2 mg/mL; 30 min) reduces the ability of HSV-2 to invade HeLa cells by approximately 80%, a result confirmed by detecting the decrease in VP16 protein levels^[1].
G2-Peptide (0.15-10 mg/mL; 1 h) inhibits plaque formation of HSV-2 in Vero cells, with an IC₅₀ of 1 mg/mL, and reaches the maximum inhibitory effect at a concentration of 2.5 mg/mL^[1].
G2-Peptide (0.03125-2 mg/mL; 1 h) dose-dependently inhibits HSV-2-induced cell-cell fusion in CHO-K1 cells expressing HSV-2 entry factors^[1].
G2-Peptide (0-0.25 mM; 60 min) potently inhibits HSV-1 entry into CHO-K1 cells expressing 3-OST-3, nectin-1 or HVEM, with an IC₅₀ of 0.02-0.03 mM, and shows no cytotoxicity at concentrations up to 0.5 mM^[2].
The G2 peptide significantly reduces glutamate exocytosis evoked at synapses of primary mouse hippocampal neurons^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.